Yutaka Kozu

Dr. Yutaka Kozu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2019 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
SSSotaro Shikano
Sotaro Shikano
YGYasuhiro Gon
Yasuhiro Gon
SMShuichiro Maruoka
Shuichiro Maruoka
TSTetsuo Shimizu
Tetsuo Shimizu
YKYutaka Kozu
Yutaka Kozu
SHShu Hashimoto
Shu Hashimoto
Acute respiratory distress syndrome (ARDS) is a life-threatening disease; however, its treatment has not yet been fully established. The progression of ARDS is considered to be mediated by altered intercellular communication between immune and structural cells in the lung. One of several factors involved in intercellular communication is the extracellular vesicle (EV). They act as carriers of functional content such as RNA molecules, proteins, and lipids and deliver cargo from donor to recipient cells. EVs have been reported to regulate the nucleotide-binding oligomerization like receptor 3 (NLRP3) inflammasome. This has been identified as the cellular machinery responsible for activating inflammatory processes, a key component responsible for the pathogenesis of ARDS. Here, we provide comprehensive genetic analysis of microRNAs (miRNAs) in EVs, demonstrating increased expression of the miRNA-466 family in the bronchoalveolar lavage fluid of a mouse ARDS model. Transfection of bone marrow-derived macrophages (BMDMs) with miRNA-466 g and 466 m-5p resulted in increased interleukin-1 beta (IL-1β) release after LPS and ATP treatment, which is an established in vitro model of NLRP3 inflammasome activation. Moreover, LPS-induced pro-IL-1β expression was accelerated by miRNA-466 g and 466 m-5p in BMDMs. These findings imply that miRNA-466 family molecules are secreted via EVs into the airways in an ARDS model, and this exacerbates inflammation through the NLRP3 inflammasome. Our results suggest that the NLRP3 inflammasome pathway, regulated by extracellular vesicle miRNA, could act as a therapeutic target for ARDS.

8 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
CHChihiro Hirano
Chihiro Hirano
YKYutaka Kozu
Yutaka Kozu
YJYusuke Jinno
Yusuke Jinno
YKYusuke Kurosawa
Yusuke Kurosawa
SYShiho Yamada
Shiho Yamada
YGYasuhiro Gon
Yasuhiro Gon
Background: Gut microbiota dysbiosis has been associated with childhood asthma; however, its role in adult bronchial asthma (BA), particularly in Japanese populations, remains unclear. The potential influence of sex-based differences also warrants investigation. We aimed to investigate the association between gut microbiota composition and adult BA in a Japanese cohort, focusing on sex-specific differences. Methods: Stool samples from 108 Japanese adults with BA (48 male and 60 female individuals) and 210 healthy controls (90 male and 120 female individuals) were analyzed using 16S rRNA gene sequencing. Analyses were stratified by sex. β-diversity was assessed using non-metric multidimensional scaling and permutational multivariate analysis of variance. Genus-level taxonomic comparisons were conducted using the ANOVA-Like Differential Expression version 2 tool on centered log-ratio-transformed data. Results: β-diversity significantly differed between the groups among both male and female individuals. In male individuals, 11 taxa had absolute effect sizes of ≥0.2. In female individuals, 19 taxa met this threshold, with 8 reaching significance after Benjamini–Hochberg correction. Streptococcus and Blautia were enriched in the BA group in both sexes, whereas other taxa showed sex-specific patterns, such as Veillonella in male and Flavonifractor and Eggerthella in female individuals. Several short-chain fatty acid (SCFA)-producing taxa were depleted in the BA group. Conclusions: Our findings suggest that gut microbiota dysbiosis occurs in Japanese adults with BA, characterized by enrichment of taxa associated with respiratory diseases and depletion of SCFA-producing bacteria. The observed patterns highlight the importance of considering sex-specific differences in future research.

4 September 2020 in Sleep and Breathing
Verified
Journal Article
Open access
PDF file
YKYutaka Kozu
Yutaka Kozu
YKYusuke Kurosawa
Yusuke Kurosawa
SYShiho Yamada
Shiho Yamada
AFAsami Fukuda
Asami Fukuda
MHMari Hikichi
Mari Hikichi
YGYasuhiro Gon
Yasuhiro Gon
Purpose: To investigate the different pathophysiologies of obstructive sleep apnea (OSA) phenotypes using cluster analysis. Differences between leptin/adiponectin levels in the resulting OSA phenotypes were also examined. Methods: In total, 1057 OSA patients were selected, and a retrospective survey of clinical records, polysomnography results, and blood gas data was conducted. Patients were grouped into four clusters by their OSA severity, PaCO2, body mass index (BMI), and sleepiness. A k-means cluster analysis was performed, resulting in a division into four subpopulations. The Tukey or Games-Howell tests were used for intergroup comparisons. Results: Among the 20 clinical OSA items, four common factors (Epworth Sleepiness Scale [ESS], BMI, Apnea-Hypopnea Index [AHI], and PaCO2) were extracted by principal component analysis, and a cluster analysis was performed using the k-means method, resulting in four distinct phenotypes. The Clusters 1 (middle age, symptomatic severe OSA) and 4 (young, obese, symptomatic very severe OSA) exhibited high leptin levels. C-reactive protein levels were also elevated in Cluster 4, indicating a different pathophysiological background. No apparent differences between clusters were observed regarding adiponectin/leptin ratios and adiponectin levels. Classification into groups based on phenotype showed that Epworth Sleepiness Scale [ESS] score and disease severity were not correlated, suggesting that sleepiness is affected by multiple elements. Conclusions: The existence of multiple clinical phenotypes suggests that different pathophysiological backgrounds exist such as systemic inflammation and metabolic disorder. This classification may be used to determine the efficacy of continuous positive airway pressure treatment that cannot be determined by the AHI.

25 April 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
HKHirofumi Kamata
Hirofumi Kamata
KTKazufumi Takamatsu
Kazufumi Takamatsu
KFKoichi Fukunaga
Koichi Fukunaga
SCShotaro Chubachi
Shotaro Chubachi
KNKensuke Nakagawara
Kensuke Nakagawara
AYAkihito Yokoyama
Akihito Yokoyama

27 February 2024 in Sleep Science
Verified
Journal Article
Open access
PDF file
TOTakashi Oki
Takashi Oki
YKYutaka Kozu
Yutaka Kozu
MHMamiko Hoshi
Mamiko Hoshi
YIYasunori Itoda
Yasunori Itoda
NFNaho Furusho
Naho Furusho
YGYasuhiro Gon
Yasuhiro Gon
Objective Leptin is an appetite-suppressing hormone released by adipose tissue that plays an important role in severe obstructive sleep apnea syndrome (OSAS). However, it is unclear whether leptin levels are a useful biomarker for this syndrome. The present study aimed to assess the effect of continuous positive airway pressure (CPAP) treatment on the syndrome according to leptin levels, using a cluster classification based on clinical features of the syndrome. Materials and Methods We performed a hierarchical cluster analysis of data from 97 OSAS patients diagnosed via polysomnography. We also evaluated the effect after 6 months of CPAP administration. Results Clusters 1 (49 patients; 50.5%) and 2 (6 patients; 6.2%) presented normal leptin levels, and clusters 3 (11 patients; 11.3%) and 4 (31 patients; 32%) presented high leptin levels. Clusters 3 and 4 presented different leptin levels, but the same degree of obesity. After treatment, the levels of excessive daytime sleepiness improved in all clusters. In Cluster 3, leptin levels were significantly reduced after treatment. Conclusion Using the conventional diagnostic method of the apnea-hypopnea index, it was not clear whether leptin is a useful biomarker for the CPAP treatment. However, it may be helpful for particular clusters, including obese women, and where particular populations require CPAP treatment.

21 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
KKKanako Kono
Kanako Kono
YKYutaka Kozu
Yutaka Kozu
SYShun Yokota
Shun Yokota
KHKouta Hatayama
Kouta Hatayama
KMKenji Mizumura
Kenji Mizumura
YGYasuhiro Gon
Yasuhiro Gon
Background/Objectives: Nontuberculous mycobacterial pulmonary disease (NTM-PD) is treated using a combination of multiple antimicrobial agents and prolonged therapy; however, recurrence and reinfection rates remain high. Susceptibility to NTM-PD is not fully understood. We aimed to investigate the association between NTM-PD and gut microbiota and determine the impact of antimicrobial therapy on the composition of the gut microbiota. Methods: We analyzed the gut microbiota of 20 Japanese females with NTM-PD (mean age: 67.9 years; range: 50–80 years) at different treatment stages—before, during, and at recurrence—alongside 20 healthy individuals, using 16S rRNA gene amplicon sequencing. Results: Subgroup A (pre-treatment) showed a small difference in β-diversity when compared with the healthy control (HC) group, while no significant differences in α-diversity were observed. Subgroup B (during treatment) exhibited a larger difference in β-diversity compared with the HC group, along with a decrease in α-diversity. The α-diversity of the gut microbiota in Subgroup C (at recurrence) was lower than that in Subgroup A but higher than that in Subgroup B. In Subgroups A and C, the bacterial taxa Sutterella, Adlercreutzia, Odoribacter, and Prevotella had decreased relative abundance, while Erysipelatoclostridium, Massilimicrobiota, Flavonifractor, Eggerthella, and Fusobacterium had increased relative abundance compared to those in the HC group. Conclusions: The loss of normal resident gut bacteria may hinder reacquisition. Treatment may be associated with the persistence of a dysbiotic gut microbiota, fostering susceptibility to NTM-PD. Gut microbiota dysbiosis may heighten susceptibility to NTM-PD, complicate treatment outcomes, and increase the risk of microbiological recurrence following therapy.